Plasmodium falciparum News and Research

RSS

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.

13 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Scientists decode stability blueprint of rhomboid enzyme

Johns Hopkins scientists have decoded for the first time the "stability blueprint" of an enzyme that resides in a cell's membrane, mapping which parts of the enzyme are important for its shape and function.

1 Aug 2012

Mapping rhomboid enzymes could eventually lead to drugs to treat malaria

31 Jul 2012

Malaria misdiagnosis: an interview with Dr Toby Leslie

Malaria is caused by a multi-staged parasite which is transmitted by the bite of infected female anopheles mosquitoes. It affects millions of people and kills more than 500,000 people throughout the world every year.

26 Jul 2012

Malaria commonly misdiagnosed and mistreated in Afghanistan

Findings published in the BMJ suggest that malaria is being significantly misdiagnosed in Afghanistan, with many patients with fever alone being given antimalarial drugs and antibiotics despite having negative laboratory results for the disease.

25 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Scientists identify inhibitors of key enzyme involved in survival of malaria parasite

An international team of scientists, led by researchers from the Department of Pediatrics at the University of California, San Diego School of Medicine, have identified the first reported inhibitors of a key enzyme involved in survival of the parasite responsible for malaria. Their findings, which may provide the basis for anti-malarial drug development, are currently published in the online version of the Journal of Medicinal Chemistry.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Intense war against malaria outlined by two studies in The American Journal of Tropical Medicine and Hygiene

A pair of provocative studies in the July 2012 issue of The American Journal of Tropical Medicine and Hygiene (AJTMH) provides a window into the intense ground war now underway against malaria.

4 Jul 2012

Transgenic mosquitoes can control malaria

Mosquitoes bred to be unable to infect people with the malaria parasite are an attractive approach to helping curb one of the world's most pressing public health issues, according to UC Irvine scientists.

13 Jun 2012

New technique accurately determines infants at risk for malaria

A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines.

6 Jun 2012

New knowledge related to host-parasite interaction in severe malaria

Researchers from Seattle Biomedical Research Institute, the University of Copenhagen and the University of Edinburgh have uncovered new knowledge related to host-parasite interaction in severe malaria, concerning how malaria parasites are able to bind to cells in the brain and cause cerebral malaria - the most lethal form of the disease.

22 May 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

Drug resistance woes hamper anti-malaria fight

Researchers have found that there is increasing resistance to the front-line treatments for malaria. A pair of studies published in The Lancet and the journal Science showed how the disease is moving fast into new territory and identified a region of the parasite's genome that may be responsible for mutating in order to survive.

5 Apr 2012

IPT has an ongoing protective effect against malaria in infants

Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.

2 Apr 2012

P. falciparum colonizes America via two separate introduction routes: Study

The malaria parasite, Plasmodium falciparum, originates from Africa, and is found on every continent. Over 200 million people are infected every year from Africa to Asia, as well as in America and the Middle East. How did it spread to the entire planet? It is not entirely clear how it conquered the New World. Scientists from the UMR Migevec and their partners have recently shown in the journal PNAS that the pathogen was introduced by ship during the slave trade.

29 Mar 2012

Simple and accurate device to study malaria

University of British Columbia researcher Hongshen Ma has developed a simple and accurate device to study malaria, a disease that currently affects 500 million people per year worldwide and claims a million lives.

29 Feb 2012

Novartis delivers 100 million child-friendly antimalarial treatments to 39 countries

One hundred million treatments of Coartem- Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced today.

23 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012